International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care

Abstract

The Oncology Pharmacy Team (OPT), consisting of specialty-trained pharmacists and/or pharmacy technicians, is an integral component of the multidisciplinary healthcare team (MHT) involved with all aspects of cancer patient care. The OPT fosters quality patient care, safety, and local regulatory compliance. The International Society of Oncology Pharmacy Practitioners (ISOPP) developed this position statement to provide guidance on five key areas: 1) oncology pharmacy practice as a pharmacy specialty; 2) contributions to patient care; 3) oncology pharmacy practice management; 4) education and training; and 5) contributions to oncology research and quality initiatives to involve the OPT. This position statement advocates that: 1) the OPT be fully incorporated into the MHT to optimize patient care; 2) educational and healthcare institutions develop programs to continually educate OPT members; and 3) regulatory authorities develop certification programs to recognize the unique contributions of the OPT in cancer patient care.

Onco-pharmacist led evaluation of knowledge, attitude & practice (KAP) of safe handling cytotoxic drugs among health care professional's (HCP's) in tertiary care hospital: A hospital based interventional Study

“…In current study, the increase in the mean score of these parameters depicts the positive effect of training the HCPs using standard guidelines while handling, preparation and administration of anti-cancer drugs by clinical onco-pharmacist Similarly, Ali et.al have demonstrated in their study that involvement of clinical oncology pharmacist plays an integral role in minimizing the adverse effect and in raising safety standards 19 while handling the CDs and also, Robert et al have highlighted the importance of the training the oncology pharmacist for the better future of oncology care 20…”

Call to Action for Improving Oral Anticancer Agent Adherence

“…42 It also aligns with the position of the International Society of Oncology Pharmacy Practitioners. 43…”

“…42 It also aligns with the position of the International Society of Oncology Pharmacy Practitioners. 43 Action 4: Cancer organizations should advocate for policies that ensure the affordability of oral anticancer drugs.…”

International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions

“…The role of oncology pharmacy practitioners (oncology pharmacists, pharmacy technicians and assistants) in this emerging field is also developing, with different health care systems adopting a number of alternative models depending on the clinical requirements of patients, the skills and experiences of oncology pharmacy practitioners, and availability of resources. 12 The advent of immunotherapy and its increasing role in the treatment of malignant disease has highlighted a need for oncology pharmacists to engage with this new treatment modality to ensure that immunotherapy agents are used safely and effectively to treat patients with malignant conditions. In many countries, oncology pharmacists are well established within the wider multidisciplinary team and play a significant role in making treatment recommendations and optimising pharmaceutical care.…”